Handelsbanken Fonder AB cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 643,246 shares of the company’s stock after selling 3,300 shares during the quarter. Johnson & Johnson comprises approximately 2.2% of Handelsbanken Fonder AB’s investment portfolio, making the stock its 6th biggest position. Handelsbanken Fonder AB’s holdings in Johnson & Johnson were worth $85,095,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently modified their holdings of JNJ. State Street Corp increased its stake in shares of Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after acquiring an additional 6,656,371 shares during the last quarter. Korea Investment CORP increased its stake in shares of Johnson & Johnson by 38.9% in the 1st quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock worth $265,296,000 after acquiring an additional 596,134 shares during the last quarter. Bank of Nova Scotia increased its stake in shares of Johnson & Johnson by 94.5% in the 1st quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock worth $145,914,000 after acquiring an additional 569,313 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth $65,598,000. Finally, CIBC World Markets Inc. increased its stake in shares of Johnson & Johnson by 111.8% in the 1st quarter. CIBC World Markets Inc. now owns 948,655 shares of the company’s stock worth $118,155,000 after acquiring an additional 500,662 shares during the last quarter. 66.00% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://ledgergazette.com/2017/09/17/johnson-johnson-jnj-shares-sold-by-handelsbanken-fonder-ab.html.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.20% during trading on Friday, reaching $134.45. The company had a trading volume of 15,522,011 shares. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08. The firm has a 50-day moving average of $132.62 and a 200 day moving average of $129.18. The firm has a market capitalization of $360.86 billion, a price-to-earnings ratio of 22.75 and a beta of 0.79.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.74 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. The ex-dividend date was Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.50%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
A number of analysts have issued reports on the company. J P Morgan Chase & Co raised their target price on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 16th. Jefferies Group LLC set a $145.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research note on Tuesday, August 15th. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $135.00 target price (up from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. Cowen and Company set a $147.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research note on Thursday, August 24th. Finally, BidaskClub downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 1st. Three analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $134.60.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.